Development and preclinical evaluation of a biodegradable ventricular septal defect occluder

Huang, Xiaolun; Zhu, Yu; Cao, Jun; Hu, Jianqiang; Bai, Yuan; Jiang, Hai-Bing; Li, Zhaofeng; Chen, Ying; Wang, Wei; Qin, Yue

doi:10.1002/ccd.24580

Cited by 20 publications

(20 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fibrous granulation tissues grew into the occluder, and the surface of the right disc was covered with tissues. Meanwhile, due to the multi‐stage hydrolysis, the material was gradually fragmented and granulated . Large degraded particles could be observed (denoted by yellow arrowheads, Figure c), which confirmed the degradability of the material.…”

Section: Resultsmentioning

confidence: 67%

4D‐Printed Biodegradable and Remotely Controllable Shape Memory Occlusion Devices

Lin

et al. 2019

Adv Funct Materials

202

143

View full text Add to dashboard Cite

Implantation of occlusion devices is an effective approach for the treatment of congenital heart diseases in the clinic. However, most commercial clinical occlusion devices are currently made of nondegradable metals, which may lead to complications such as perforation, allergies, and erosion. In this work, 4D-printed novel, biodegradable, remotely controllable, and personalized shape memory occlusion devices are demonstrated and atrial septal defect occluders are exemplified. By incorporating Fe 3 O 4 magnetic particles into the shape memory poly(lactic acid) matrix, the deployment of the occluders can be controlled remotely after implantation. The excellent cytocompatibility and histocompatibility are conducive to cell adhesion and ingrowth of granulation tissues into the occluders, thus facilitating rapid endothelialization. In addition, personalized shape memory occluders ensure an ideal fit and provide sufficient support for defects. Therefore, 4D-printed shape memory occluders can be used as a potential substitute for metal occlusion devices.

show abstract

Section: Resultsmentioning

confidence: 67%

4D‐Printed Biodegradable and Remotely Controllable Shape Memory Occlusion Devices

Lin

et al. 2019

Adv Funct Materials

202

143

View full text Add to dashboard Cite

show abstract

“…Although the PLLA skeleton was still partly undegraded after 2 years in vivo, the molecular weight showed a distinct decrease during the follow‐up. And during the whole follow‐up, only mild‐to‐moderate inflammatory response was observed, which might be explained as the healing response …”

Section: Discussionmentioning

confidence: 97%

A novel totally biodegradable device for effective atrial septal defect closure: A 2‐year study in sheep

Ouyang

Wang

et al. 2018

J Interven Cardiology

View full text Add to dashboard Cite

show abstract

“…Atrial septal defects (ASDs) are the most common types of congenital heart defects (CHDs) and typically present with left to right shunts, which account for up to 10% and 40% of all CHDs, respectively ( Penny and Vick, 2011 ; Rao and Harris, 2017 ). The patients with ASDs may exhibit poor growth and development, decreased activity tolerance, repeated respiratory infections, and hyperhidrosis, and they are accompanied by heart enlargement, increased pulmonary circulation pressure and resistance, heart failure, and atrial arrhythmia ( Huang et al, 2013 ; Leppert et al, 2016 ; Karunanithi et al, 2017 ; Wu et al, 2018 ; Pillai et al, 2019 ). Surgery as the traditional method to treat ASDs has several disadvantages including large trauma, long recovery time and permanent scar left.…”

Section: Introductionmentioning

confidence: 99%

“…It is more serious that residual septal defects are frequently associated with surgery-related side-effect complications, such as reoperation, infection, sternotomy scarring, and even death ( Gaynor et al, 2001 ; Oses et al, 2010 ). To avoid those side effects of surgery, interventional closure has been developed to the main treatment to septal defects ( Huang et al, 2013 ; Shimpo et al, 2013 ; Morray, 2019 ).…”

Section: Introductionmentioning

confidence: 99%

Key Regulatory Differentially Expressed Genes in the Blood of Atrial Septal Defect Children Treated With Occlusion Devices

Tang

Yue-jin

et al. 2021

Front. Genet.

View full text Add to dashboard Cite

Atrial septal defects (ASDs) are the most common types of cardiac septal defects in congenital heart defects. In addition to traditional therapy, interventional closure has become the main treatment method. However, the molecular events and mechanisms underlying the repair progress by occlusion device remain unknown. In this study, we aimed to characterize differentially expressed genes (DEGs) in the blood of patients treated with occlusion devices (metal or poly-L-lactic acid devices) using RNA-sequencing, and further validated them by qRT-PCR analysis to finally determine the expression of key mediating genes after closure of ASD treatment. The result showed that total 1,045 genes and 1,523 genes were expressed differently with significance in metal and poly-L-lactic acid devices treatment, respectively. The 115 overlap genes from the different sub-analyses are illustrated. The similarities and differences in gene expression reflect that the body response process involved after interventional therapy for ASDs has both different parts that do not overlap and the same part that crosses. The same portion of body response regulatory genes are key regulatory genes expressed in the blood of patients with ASDs treated with closure devices. The gene ontology enrichment analysis showed that biological processes affected in metal device therapy are immune response with CXCR4 genes and poly-L-lactic acid device treatment, and the key pathways are nuclear-transcribed mRNA catabolic process and proteins targeting endoplasmic reticulum process with ribosomal proteins (such as RPS26). We confirmed that CXCR4, TOB1, and DDIT4 gene expression are significantly downregulated toward the pre-therapy level after the post-treatment in both therapy groups by qRT-PCR. Our study suggests that the potential role of CXCR4, DDIT4, and TOB1 may be key regulatory genes in the process of endothelialization in the repair progress of ASDs, providing molecular insights into this progress for future studies.

show abstract

Development and preclinical evaluation of a biodegradable ventricular septal defect occluder

Abstract: The BD occluder proved safe and effective for VSD closure. This device is characterized by compatible mechanical properties, a fully BD property, and a good match between the degradation of occluder and the healing response of organism.

Cited by 20 publications

References 26 publications

4D‐Printed Biodegradable and Remotely Controllable Shape Memory Occlusion Devices

4D‐Printed Biodegradable and Remotely Controllable Shape Memory Occlusion Devices

A novel totally biodegradable device for effective atrial septal defect closure: A 2‐year study in sheep

Key Regulatory Differentially Expressed Genes in the Blood of Atrial Septal Defect Children Treated With Occlusion Devices

Contact Info

Product

Resources

About